AGORA Cancer Research Center
AGORA was inspired by the vision that the integration of progress in cancer research into clinical practice can be accelerated by bringing together interdisciplinary research teams of clinicians, cancer biologists, immunologists, bio-informaticians and bio-engineers. Initiated by the ISREC Foundation in 2013, the AGORA building was opened in 2018. The functioning of this translational cancer research center reflects a partnership between the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL), the Swiss Federal Institute of Technology of Lausanne (EPFL), the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE).
Latest news
Events
Oncology Grand Rounds, Post ESMO – Part Two | November 6th
Events
15 th Faculty & Staff Annual Retreat, Swiss Cancer Center Leman | November 2nd and 3rd
Events
PhD Thesis Defense | November 13th
Events
You are invited: AGORA Apéro | November 5th
Events
DOF Seminar, Dr. Lukas Altenburger | November 18th
Events
Ludwig Distinguished Lecture, Prof. John Wherry | November 19th
Events
DOF Seminar, Prof. Renato Ostuni | November 25th
Events
Save the Date – AGORA Platform Tour
Events
Ludwig Distinguished Lecture, Prof. Ilaria Malanchi | December 3rd
Latest publications
Strategies to develop therapeutic cancer vaccines for pancreatic cancer.
Coppi MM, Graciotti M, Digklia A, Kandalaft LE
The lancet. Gastroenterology & hepatology – 2026 Oct 14
LuTuFlow: a deep learning-based pipeline for quantitative characterization of mouse lung tumors in CT imaging.
Liu Y, Li L, Wittwer M, (…), Dapia B, Andò E, De Palma M
bioRxiv – 2026 Oct 14
Familial Pancreatic Cancer Associated with a Shared BRIP1 Variant: Implications for Homologous Recombination Deficiency and Targeted Therapy.
Degrauwe N, Dei Tos G, Trimech M, Homicsko K, Digklia A
Genes – 2026 Sep 29
Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.
Macchia G, Morganti AG, Taylor A, (…), Herrera FG, Jereczek-Fossa BA, Guckenberger M
The Lancet. Oncology – 2026 Sep 28
Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency.
Tao R, Erkek-Ozhan S, Xu B, (…), Peng JC, Pfister SM, Northcott PA
Nature genetics – 2026 Sep 24
